Is It Time To Sell AstraZeneca plc And Buy GlaxoSmithKline plc?

Should you be a contrarian when investing in AstraZeneca plc (LON:AZN) and GlaxoSmithKline plc (LON:GSK)?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

So the heyday of the pharmaceutical industry is over. Many blockbuster drugs have tumbled over the patent cliff, and there are now a range of ‘me-too’ drugs which produce a fraction of the revenues of the big drugs of yesteryear.

This is what many investors think, and there is much truth in this. But if you heard the news in recent weeks of a series of cancer drugs which combat this terrible disease through the immune system, then you will know there is a future for pharma. Antibody-based drugs, stem cell science and vaccines are some of the ways this sector can find new paths to growth. However, I think investors should invest carefully when they buy into these businesses, as much of the low-hanging fruit has long ago been picked.

AstraZeneca’s fortunes have been transformed

So which of the drug companies should you buy into? Much has been written about UK pharma stalwarts AstraZeneca (LSE: AZN) and GlaxoSmithKline (LSE: GSK). AstraZeneca was, a few years ago, seen as the laggard of the sector, with a whole series of patent expiries taking place over the past few years.

But chief executive Pascal Soriot has transformed this company, making it more forward looking, and it has a big stake in those money-spinning anti-cancer drugs. For this reason, the fall in profitability has reversed, and AstraZeneca’s share price has been rising.

But actually, this company is off its highs, and is still reasonably priced. The 2015 P/E ratio is 14.93, with a dividend yield of 4.60%. The 2016 P/E ratio is 15.95, with the dividend yield rising to 4.77%.

GlaxoSmithKline is no longer the darling of the sector

Compare this with GSK. This firm was the darling of the pharmaceutical industry a few years ago, with much written about what was thought of as one of the best drugs pipelines in the sector. The share price rose to 1750p, and many shareholders, including myself, made a healthy profit. But I was a little sceptical about how much higher the share price could go, and so I sold just short of the peak.

Soon afterwards, the company was caught up in the Chinese bribery scandal, and investors started to realise that what should have been blockbusters were mainly niche art house numbers. The rapid rise in profitability hasn’t happened, with earnings per share in 2016 likely to be little different from those in 2012. And so the share price has been falling.

At 1338p, GlaxoSmithKline looks a lot cheaper. How does it compare with AZN? Well, the 2015 P/E ratio is 15.23, with a dividend yield of 6.08%. And the 2016 P/E ratio is 14.49, with a dividend yield of 6.02%.

Taking a strictly contrarian view, if AstraZeneca’s share price has risen a lot, it should be time to sell. And GSK’s sinking share price should mean it is time to buy. Except I don’t think it’s as simple as that.

My view is that it is now Astra that has the stronger drugs portfolio. Its strength in anti-cancer drugs particularly impresses me. That’s why I think you should buy AstraZeneca and sell GlaxoSmithKline. I guess Astra just happens to have chanced upon the best balance of strategic vision and good, old-fashioned luck.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Prabhat Sakya has no position in any shares mentioned. The Motley Fool UK has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Young black colleagues high-fiving each other at work
Investing Articles

2 FTSE 100 value stocks I’d buy for my Stocks and Shares ISA in March!

Now could be a great time for fans of FTSE 100 value stocks to go investing. Here are a couple…

Read more »

Three signposts pointing in different directions, with 'Buy' 'Sell' and 'Hold' on
Investing Articles

Looking for value stocks? Here’s 1 I’d buy and 1 I’d avoid!

This Fool delves deeper into two value stocks she’s had her eye on and explains why she’s bullish on one,…

Read more »

Young black woman using a mobile phone in a transport facility
Investing Articles

With the Airtel Africa share price in pennies, is it a bargain?

With the Airtel Africa share price having slumped by a quarter in just one month, this shareholder considers some of…

Read more »

Asian man looking concerned while studying paperwork at his desk in an office
Investing Articles

Are these 2 defensive FTSE 100 stocks shrewd buys after recent updates?

This Fool takes a closer look at these FTSE 100 stocks. She admires their defensive traits -- but does that…

Read more »

Portrait of elderly man wearing white denim shirt and glasses looking up with hand on chin. Thoughtful senior entrepreneur, studio shot against grey background.
Investing Articles

The FTSE 100 closes up after full-year results from leading UK firms – are they buys?

Earnings season brings about a lot of ups and downs for the FTSE 100. Yesterday had some particularly good releases,…

Read more »

artificial intelligence investing algorithms
Investing Articles

Should I buy NVIDIA stock as a British investor?

NVIDIA stock is up two-thirds this year alone. Our writer considers some pros and cons, specifically given that he is…

Read more »

Investing Articles

With £2,000 in excess savings, I’d buy 41 shares in this Warren Buffett dividend stock

Stephen Wright thinks one of the best dividend shares to buy right now might be a Warren Buffett stock that’s…

Read more »

Investing Articles

How many Aviva shares do I need to collect a £100 monthly income?

Aviva shares are well suited for passive income purposes. Our writer works out how many would be needed for a…

Read more »